While using the body’s own immune system as a therapeutic approach to fight cancer is not a new concept in oncology, recent successes in clinical studies are making immunotherapy a reality, as it exploits the antitumor capabilities of resident immune cells within the body. This white paper provides an overview of the immune system and its role in cancer immunity, including: Checkpoint inhibitors as immunotherapeutic agents CTLA-4 – The first immune checkpoint receptor to be clinically targeted Blocking PD-1/PD-L1 New therapeutics, new problems: understanding tumor flare Download our white paper today to discover how immunotheraphy has brought new hope to oncology clinical trials.

As we know, more attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated or thoroughly defined during drug development. Discovering negative results for BP elevation in early trials, would allow more informed planning for BP safety monitoring in later trials. Download the publication to discover a systematic approach to identifying blood pressure effects during typical Phase I and Phase II trials, including: Justification for improved BP assessment Systematic evaluation of BP effects: a working checklist Proposed BP assessments during early human testing